Acute Agitation in Emergency Psychiatry

Recruiting Phase 2 Phase 3 Interventional Study
Agitation
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 64
Sex
Any
Trial phase
Phase 2/3
Study type
Interventional
Purpose
Treatment
Participants needed
132 (estimated)
Sponsor
Lone Baandrup · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The purpose of the study is to improve the pharmacological treatment of psychiatric patients with acute agitation.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * 18-64 years * Agitation with the need for tranquillization in inpatient psychiatric settings including psychiatric emergency rooms * Total score of ≥14 on the PANSS Excited Component (PEC) * A score ≥4 on at least 1 of the 5 items of the PEC * Informed consent obtained prior t…
Contacts

Lone Baandrup, MD, DMSc

00 45 91165903

lone.baandrup@regionh.dk

CONTACT

Marie Vang Jensen, MD

0045 6199 7358

marie.said.vang.jensen@regionh.dk

CONTACT